TRIAL DETAIL
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 07/01/2011 |
Age of Trial (yrs) 13.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K/mTOR inhibitor + MEK inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CMEK162X2103, EudraCT 2011-000421-74 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Pharmaceuticals 800-340-6843 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| Combined inhibition of MAP kinase and KIT signaling effectively destabilizes the ETV1 protein and synergistically suppresses GIST tumorigenesis |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
610 University Ave |
Toronto |
ON |
M5G 2M9 |
Canada |
|
Villejuif |
Val de Narne |
94805 |
France |
||
Grattan Street |
Parkville |
Victoria |
3050 |
Australia |
|
119-129 |
Barcelona |
08035 |
Spain |
||
Hufelandstr. 55 |
Essen |
45122 |
Germany |
||
Cologne |
D-50924 |
Germany |
|||
Madison |
WI |
53792 |
USA |
||
55 Fruit Street |
Boston |
MA |
02114 |
USA |